# NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

> Tender notice from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Tender value: £2,028,332,000
- Published: 17 February 2025
- Planned start: 1 September 2025
- Planned end: 31 August 2027
- Stage: open_tender
- Procurement category: goods
- Notice ID: 8c603c5e-25d4-4ab4-8bb9-504458a54727-826898
- OCID: ocds-b5fd17-1266d8b9-9f94-4443-a0a5-21d13bc7faa8

## Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East\. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE\. Period of Framework Agreement: 01 September 2025 to 31 August 2026 Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family\.force\.com/s/Welcome\. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis\.co\.uk

## Related contract awards

- [Modernising Education in TEL \(METEL\)](/contracts/ocds-b5fd17-f813e1f0-8dd4-4119-ba64-a1107d65501a): NHS England
- [NHS Online](/contracts/ocds-b5fd17-c65a69a7-ee33-4b4e-af0e-60156636c859): NHS England
- [CQC Well Led Financial Governance Assessor 26\_27](/contracts/ocds-b5fd17-0fc6347f-43a7-4f91-8b00-7372439b5969): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/8c603c5e-25d4-4ab4-8bb9-504458a54727-826898)